Burak ÖZ, Faruk KILINÇ, Ramazan ULU, Süleyman AYDIN, Süleyman Serdar KOCA, Ahmet KARATAŞ, Mesude Seda KINACI, Nevzat GÖZEL, Emir DÖNDER, Fatih DEMİRCAN, Meltem YARDIM

Plasma urotensin II levels in primary Raynaud's phenomenon and systemic sclerosis

Background/aim: The pathogenesis of Raynaud s phenomenon (RP) has not yet been fully elucidated. RP is characterized by exaggerated cold-induced vasoconstriction. Urotensin II (UII) is a potent vasoconstrictor. The aim of the present study was to evaluate plasma UII levels in both primary RP and secondary RP associated with systemic sclerosis (SSc). Materials and methods: Fifteen patients with primary RP, 30 patients with RP secondary to SSc, and 30 healthy controls (HC) were included in the study. Raynaud condition scores (RCS) were determined in the primary RP and SSc groups. Modified Rodnan skin score (MRSS) was determined for the SSc patients. Plasma UII level was analyzed by the ELISA method. Results: When compared to the HC group, plasma UII level was lower in the secondary RP group, but not in the primary RP group. Plasma UII level was not directly related to RCS in either the primary or secondary RP group. Moreover, it was not correlated with MRSS in the secondary RP group. Conclusion: The results of the present study suggest that UII is not associated with primary RP. Its level was lower in the secondary RP (SSc) patients. Therefore, it can be concluded that decreased UII level is related to SSc instead of RP.

PDF

___

1. Boin F, Wigley FM. Understanding, assessing and treating Raynauds phenomenon. Curr Opin Rheumatol 2005; 17: 752- 760.
2. Wigley FM. Clinical practice. Raynauds phenomenon. N Engl J Med 2002; 347: 1001-1008.
3. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
4. Zamora MR, OBrien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynauds phenomenon. Lancet 1990; 336: 1144-1147.
5. Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev 2015; 67: 214-258.
6. Peng H, Zhang M, Cai X, Olofindayo J, Tan A, Zhang Y. Association between human urotensin II and essential hypertension-a 1:1 matched case-control study. PLoS One 2013; 8: e81764.
7. Buyukhatipoglu H, Buyukaslan H, Pehlivan Y, Ceylan N, Ulas T, Tarakcioglu M, Onat AM. Increased urotensin-II activity in patients with Raynauds phenomenon and systemic lupus erythematosus. Int J Rheum Dis 2011; 143: 276-281.
8. LeRoy EC, Medsger TA Jr. Raynauds phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10: 485-488.
9. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-1755.
10. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr et al. Measuring disease activity and functional status in patients with scleroderma and Raynauds phenomenon. Arthritis Rheum 2002; 46: 2410-2420.
11. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna PP, Khanna D. Course of modified Rodnan skin score in systemic sclerosis clinical trials: analysis of 3 large multicenter, randomized clinical trials. Arthritis Rheum 2009; 60: 2490-2498.
12. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000; 131: 441-446.
13. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001; 19: 2185-2190.
14. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J. Inhibition of insulin release by urotensin II: a study on the perfused rat pancreas. Horm Metab Res 2001; 33: 379-381.
15. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Polland K. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000; 130: 201-204.
16. Totsune K, Takahashi K, Arihara Z, Sone M, Murakami O, Ito S, Kikuya M, Ohkubo T, Hashimoto J, Imai Y. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004; 25: 1809- 1814.
17. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004; 176: 117-123.
18. Russell FD, Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res 2004; 63: 673-681.
19. Babińska M, Holecki M, Prochaczek F, Owczarek A, Kokocińska D, Chudek J, Więcek A. Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome? Arch Med Sci 2012; 8: 449-454.
20. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. Peptides 2008; 29: 770-777.
21. Liu LM, Zhao L, Liang DY, Yu FP, Ye CG, Tu WJ, Zhu T. Effects of urotensin-II on cytokines in early acute liver failure in mice. World J Gastroenterol 2015; 21: 3239-3244.
22. Allanore Y, Avouac J, Denton CP, Matucci-Cerinic M. Systemic sclerosis. In: Bijlsma JWL, editor. EULAR Textbook on Rheumatic Diseases. London, UK: BMJ Publishing Group Ltd.; 2013. pp. 546-567.
23. Pehlivan Y, Onat AM, Comez G, Babacan T. Urotensin-II in systemic sclerosis: a new peptide in pathogenesis. Clin Rheumatol 2011; 30: 837-842.
24. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.
25. Qi J, Du J, Tang X, Li J, Wei B, Tang C. The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart Vessels 2004; 19: 81- 88.
26. Demir T, Turkbeyler I, Kaplan DS, Pehlivan Y, Orkmez M, Tutar E, Taysi S, Kisacik B, Onat AM, Bagci C. Effectiveness of palosuran in bleomycin-induced experimental scleroderma. Inflammation 2013; 36: 75-79.
27. Mosenkis A, Kallem RR, Danoff TM, Aiyar N, Bazeley J, Townsend RR. Renal impairment, hypertension and plasma urotensin II. Nephrol Dial Transplant 2011; 26: 609-614.
28. Gigante A, Rosato E, Massa R, Rossi C, Barbano B, Cianci R, Molinaro I, Amoroso A, Salsano F. Evaluation of chronic kidney disease epidemiology collaboration equation to estimate glomerular filtration rate in scleroderma patients. Rheumatology 2012; 51: 1426-1431.